2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Squamous Cell Carcinoma of Head and Neck
4
Lung Neoplasms
3
Melanoma
2
Head and Neck Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Squamous Intraepithelial Lesions
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Liver Diseases
1
Liposarcoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Breast Neoplasms
1
Interventions
Sorafenib
5
Blood Specimen Collection
4
lenvatinib
3
sintilimab
2
pembrolizumab
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
ozanimod
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Adjuvants, Pharmaceutic
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled